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or higher, but they are safer and more conve‑
nient.7,8 In a meta ‑analysis of pivotal phase 3 AF 
randomized controlled trials (RCTs), NOACs re‑
duced the risk of stroke or SE by 19% compared 
with warfarin (relative risk [RR], 0.81; 95% CI, 
0.73–0.91), largely due to a markedly lower rate of 
hemorrhagic strokes (RR 0.49, 95% CI, 0.38–0.64) 
and intracranial bleeding (ICB) (RR, 0.48; 95% CI, 
0.39–0.59).9 However, the use of NOACs (in par‑
ticular, full ‑dose dabigatran and rivaroxaban) 
was significantly associated with an increased 
risk of gastrointestinal (GI) bleeding (RR, 1.25; 
95% CI, 1.01–1.55).7 Of note, the differences 
between baseline stroke and bleeding risks 
among different NOAC trials could have affect‑
ed the reported bleeding rates (FIGURE 1). Residu‑
al incidence of stroke or SE despite NOAC use 
among patients with AF is estimated at 1.5% 
to 2.5% per year and that of major bleeding 
at 2% to 4% per year.9 As compared with war‑
farin, NOACs slightly reduced all ‑cause mor‑
tality (RR, 0.89; 95% CI, 0.85–0.94), vascular 
mortality (RR, 0.88; 95% CI, 0.82–0.94), and 
Introduction Atrial fibrillation (AF) is the most 
common sustained cardiac arrhythmia in clini‑
cal practice, and it is associated with an increased 
risk of ischemic stroke and systemic thromboem‑
bolism (SE) from less than 1% to about 20% per 
year.1 Of all ischemic strokes, 20% to 30% are as‑
sociated with AF and high morbidity and mortal‑
ity. Oral anticoagulation therapy reduces the risk 
of stroke and SE by more than 60% in patients 
with AF,2,3 yet clinicians and patients need to con‑
sider these benefits as compared with the risk 
of major bleeding.4
Non–vitamin K antagonist oral anticoagulants 
(NOACs, or direct oral anticoagulants [DOACs] 
as recommended by the International Society 
on Thrombosis and Hemostasis [ISTH], includ‑
ing dabigatran, rivaroxaban, apixaban, and edox‑
aban), have been shown in landmark phase 3 ran‑
domized trials to be at least noninferior to war‑
farin for the prevention of stroke and SE and are 
preferred over warfarin in patients with nonval‑
vular AF.5,6 When compared with vitamin K an‑
tagonist (VKA), the efficacy of NOACs is similar 
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ABSTRACT
Major bleeding (especially intracranial hemorrhage) is the most feared adverse event observed in patients 
with atrial fibrillation (AF) receiving oral anticoagulation. Clinical risk factor–based scores have modest 
ability to predict major or clinically relevant bleeds, and blood biomarkers are increasingly implemented 
to improve bleeding prognostication in patients with AF on life ‑long anticoagulation. To improve the safety 
of anticoagulation in the era of non–vitamin K antagonist oral anticoagulants (NOACs, or direct oral 
anticoagulants [DOACs], including dabigatran, rivaroxaban, apixaban, and edoxaban), specific demographic, 
clinical, and laboratory variables should be considered. The current review summarizes practical challenges 
in the management of oral anticoagulation with emphasis on the risk assessment tools, elderly 
or underweight patients, cancer patients, impact of chronic kidney disease, liver cirrhosis, 
and thrombocytopenia in the context of bleeding risk in patients with AF.
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with warfarin (RR, 1.50; 95% CI, 1.19–1.89),17 
whereas in the ROCKET ‑AF (Rivaroxaban Once‑
‑daily Oral Direct Factor Xa Inhibition Com‑
pared with Vitamin K Antagonism for Preven‑
tion of Stroke and Embolism Trial in Atrial Fi‑
brillation), rivaroxaban 20 mg once daily in‑
creased this annual risk by 1% (3.2% vs 2.2%).18 
Of note, NOAC ‑associated GI bleeding is prob‑
ably related to the presence of the active drug 
in the GI tract, thus facilitating bleeding from 
vulnerable lesions.19
Scoring systems to predict bleeding in atrial 
fibrillation  The most commonly used defini‑
tion of major bleeding in nonsurgical patients 
according to the ISTH includes:
1	 fatal bleeding, and / or
2	 symptomatic bleeding in a critical area or or‑
gan, for example, intracranial, intraspinal, intra‑
ocular, retroperitoneal, intraarticular or pericar‑
dial, or intramuscular bleeding with compart‑
ment syndrome, and / or
3	 bleeding accompanied by a decrease in the he‑
moglobin level of 2 g/dl or higher or leading to 
transfusion of 2 or more units of whole blood or 
packed red blood cells.20
The annual rates of major bleeding range from 
1.3% to 7.2% in patients with AF on VKA treat‑
ment.21 Various bleeding risk scores (TABLE 1) have 
been developed to assess the risk of bleeding in 
patients with AF taking oral anticoagulant ther‑
apy.2 2,23 All these scores have a relatively modest 
ability to predict bleeding events (as reflected 
bleeding ‑related mortality (RR, 0.54; 95% CI, 
0.44–0.67).10 Importantly, in the phase 3 AF 
trials, NOACs were more effective than warfa‑
rin in the prevention of stroke or SE among pa‑
tients with AF aged 75 years or older.11
A systematic review by Chai ‑Adisaksopha 
et al,12 which included 12 RCTs involving 102 607 
patients at the average age of 70 to 73 years in 
the 5 AF trials and 54 to 57 years in the 7 venous 
thromboembolism (VTE) trials, clearly dem‑
onstrated that the incidence of ICB, the most 
feared hemorrhagic adverse event, in patients 
receiving NOACs is reduced by over 50% com‑
pared with warfarin. Of all major bleeding ep‑
isodes among VKA users, 8.7% were ICB with 
a 46% to 55% mortality rate.13,14 Patients with 
AF or VTE on NOACs had a lower risk of over‑
all major bleeding (RR, 0.72; number needed 
to treat [NNT], 156), fatal bleeding (RR, 0.53; 
NNT, 454), clinically relevant nonmajor bleeding 
(RR, 0.78; NNT, 99), and all bleeding (RR, 0.76; 
NNT, 18), without increased risk of GI bleed‑
ing (RR, 0.94; 95% CI, 0.88–1.34).12 Several sys‑
tematic reviews comparing NOACs with stan‑
dard care demonstrated a 20% higher GI bleed‑
ing rate in patients on a NOAC.15,16 A significant 
increase in the risk of GI bleeding was observed 
in the RCTs evaluating dabigatran and rivarox‑
aban in patients with AF.17,18 In the RE ‑LY (Ran‑
domized Evaluation of Long ‑Term Anticoagula‑
tion Therapy) trial, dabigatran 150 mg bid (but 
not dabigatran 110 mg bid) was associated with 
an increased risk of major GI bleeding compared 
FIGURE 1   Differences in thromboembolic and bleeding risk in seminal randomized controlled trials on non–vitamin K 
antagonist oral anticoagulants in atrial fibrillation 
Abbreviations: CHADS2, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack 
history; HAS ‑BLED, hypertension, abnormal liver function, history of stroke or thromboembolism, history of bleeding, age >65 
years, use of nonsteroidal anti ‑inflammatory drugs, and alcohol abuse; RE ‑LY, Randomized Evaluation of Long ‑Term 
Anticoagulation Therapy; ROCKET‑AF, Rivaroxaban Once ‑daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism 
for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; ARISTOTLE, Apixaban for Reduction in Stroke and Other 
Thromboembolic Events in Atrial Fibrillation
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thromboembolism, history of bleeding or bleed‑
ing diathesis [eg, severe anemia], age >65 years, 
use of aspirin or nonsteroidal anti ‑inflammatory 
drugs, and alcohol abuse) score had the best ev‑
idence for predicting bleeding risk (moderate 
strength of evidence), consistent with other sys‑
tematic reviews and meta ‑analyses comparing 
bleeding risk prediction scores.35,36
by the C statistic values in the range from 0.5 
to 0.65), and numerous studies comparing 2 or 
more bleeding risk scores yielded conflicting 
results.24 -33 In a systemic review commissioned 
by the Patient ‑Centered Outcomes Research In‑
stitute3 4 of 38 studies on bleeding risk predic‑
tion, the HAS ‑BLED (hypertension, abnormal 
renal and / or liver function, history of stroke or 
TABLE 1	 The	most	common	clinical	bleeding	scores	used	in	patients	with	atrial	fibrillation
Scale Risk	factors Scoring	point Bleeding	risk	stratification
HAS ‑BLED Hypertension (SBP >160 mm Hg) 1 Low risk, 0–2
High risk, 3–9Abnormal renal and/or liver function 1 point each
Stroke 1
Bleeding history 1
Labile INR 1
Elderly (>65 y) 1
Drugs (antiplatelets / NSAIDs) / concomitant / ≥8 units alcohol per week) 1 point each
HEMORR2HAGES Hepatic or renal disease 1 Low risk, 0–1
Intermediate risk, 2–3
High risk, 4–12
Ethanol abuse 1
Malignancy 1
Older (>75 y) 1
Reduced platelet count 1
Re ‑bleeding risk 2
Hypertension (uncontrolled) 1
Anemia 1
Genetic CYP2C9 polymorphisms 1
Excessive fall risk 1
Stroke / TIA history 1
ATRIA Anemia 3 Low risk, 0–3
Intermediate risk, 4
High risk, 5–10
Severe CKD 3
Age ≥75 y 2
Previous bleeding 1
Hypertension 1
ORBIT ‑AF Age (≥75 y) 1 Low risk, 0–2
Medium, risk 3
High risk ≥4
Reduced hemoglobin (<13 g/dl in men and <12 g/dl in women) 2
Hematocrit (<40% in men and <36% in women) or history of anemia 2
Bleeding history 2
Insufficient kidney function (eGFR <60 ml/min/1.73 m2) 1
Treatment with an antiplatelet agent 1
ABC ‑bleeding score Age Digitally 
calculated
Low risk <1% per year
Moderate risk, 1%–2% per year
High risk >2% per year
Biomarkers (growth differentiation factor ‑15, high ‑sensitivity cardiac 
troponin T, hemoglobin / hematocrit)
History of previous bleeding
Abbreviations: ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HEMORR2HAGES, 
Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re ‑Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall 
Risk and Stroke; INR, international normalized ratio; NSAID, non ‑steroidal anti ‑inflammatory drug; ORBIT ‑AF, Outcomes Registry for Better Informed Treatment of Atrial 
Fibrillation; SBP, systolic blood pressure; TIA, transient ischemic attack; others, see FIGURE 1
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lower clot permeability had an increased risk 
of ischemic stroke or transient ischemic at‑
tack (TIA) (hazard ratio [HR], 6.55; 95% CI, 
2.17–19.82) and major bleeds (HR, 10.65; 95%CI, 
3.52–32.22), while patients with high permea‑
bility had elevated risk of minor bleeding com‑
pared with those with low fibrin clot permeabil‑
ity (11.63% per year vs 3.55% per year).45 Hypo‑
fibrinolysis, as reflected by prolonged clot lysis 
time, resulted in an 8 ‑fold increase in stroke 
or TIA rate in AF patients on a VKA (8.67% per 
year vs 1.1% per year).46 It was also observed 
that in patients with AF on rivaroxaban, lower 
plasma clot permeability, determined as 24 to 
30 hours since the intake of rivaroxaban, pre‑
dicted ischemic cerebrovascular events (HR, 
6.64; 95% CI, 2.2–20.1) and major bleedings 
(HR 7.38; 95% CI, 2.58–21.10), but not deaths, 
during follow ‑up.47,4 8 Minor persistent bleed‑
ing was associated with increased clot perme‑
ability in patients with AF on rivaroxaban.47 
Recently, an association between higher OR‑
BIT bleeding risk score along with enhanced fi‑
brinolysis and looser clot structure in AF has 
been reported.33 Despite still poorly understood 
mechanisms underlying the above observa‑
tions, it might be speculated, based on experi‑
mental work, that denser clot meshwork with‑
in thrombi in vessels impair wound healing and 
adversely affect cell adhesion, migration, prolif‑
eration, which might enhance bleeding in par‑
ticular from the GI tract.49 It remains to be es‑
tablished whether assessing abnormalities in 
fibrin network structure in AF may be helpful 
in predicting bleeding events during treatment 
with VKA and NOAC.
Specific atrial fibrillation patient popula-
tions at risk of bleeding on anticoagulation 
Advanced age  Older patients have a higher risk 
of bleeding; however, in the age group above 
75 years, reduced ICB and increased GI bleed‑
ing on NOACs as compared with VKA share 
the same pattern as that observed in younger pa‑
tients with AF.9 In phase 3 AF trials, there were 
some differences in the bleeding risk in patients 
aged 75 years or older depending on the specif‑
ic anticoagulants (FIGURE 2). Assessment of NOACs 
in elderly patients with AF showed increased 
rates of extracranial major bleeding in those re‑
ceiving both doses of dabigatran,50 and similar 
rates of bleeding regardless of age were report‑
ed in RCTs with apixaban, edoxaban, or rivar‑
oxaban.51-53 Compared with warfarin, only apix‑
aban was associated with a lower risk of major 
bleeding in patients above 75 years.53,5 4
Low body mass The  risk of all ‑cause death, 
stroke and SE, and major bleeding is higher in 
anticoagulated patients with lower weight com‑
pared with those with normal weight.55 Low body 
weight may increase exposure to any NOAC and 
The latest AF guidelines issued by the Europe‑
an Society of Cardiology in 2016 were focused on 
modifiable risk factors and their elimination, if 
possible, including the use of antiplatelet agents, 
alcohol abuse, unstable anticoagulation with 
a VKA, and uncontrolled hypertension (to re‑
duce the risk of ICB).7 However, nonmodifiable 
bleeding risk factors such as prior major bleed‑
ing or stroke, cancer, or advanced age should 
not be ignored. Whereas modifiable bleeding 
risk factors should be identified and managed, 
the important interaction between these and 
nonmodifiable bleeding risk factors should be ac‑
knowledged, and such high ‑risk patients should 
be scheduled for an earlier and more frequent 
clinical follow ‑up after oral anticoagulant ther‑
apy has been initiated. Indeed, a formal bleed‑
ing risk assessment using the HAS ‑BLED score 
has been shown to be superior to the less well‑
‑structured approach of addressing modifiable 
bleeding risk factors only.37-39
Potential new biomarkers in bleeding predic-
tion  Most risk prediction models for bleeding 
in patients with AF, including HAS ‑BLED, ATRIA 
(Anticoagulation and Risk Factors in Atrial Fi‑
brillation), and ORBIT ‑AF (Outcomes Registry 
for Better Informed Treatment of Atrial Fibril‑
lation) score, do not incorporate biomarkers, al‑
though they may improve discrimination of tra‑
ditional risk scores. In the ARISTOTLE (Apixa‑
ban for Reduction in Stroke and Other Throm‑
boembolic Events in Atrial Fibrillation) trial 
comparing apixaban with warfarin, blood bio‑
markers, namely high ‑sensitivity cardiac tropo‑
nin T, growth differentiation factor 15, and he‑
moglobin or  hematocrit showed stronger asso‑
ciation with bleeding than most of clinical pa‑
rameters.40 The ABC ‑bleeding score including 
those 3 biomarkers was validated in the popu‑
lation of the RE ‑LY trial and performed better 
than the HAS ‑BLED and ORBIT scores.41 How‑
ever, these biomarkers are also nonspecifically 
associated with other cardiovascular outcomes 
(eg, stroke, death, heart failure)42 and some are 
not readily available in routine clinical practice.
Other biomarkers reflecting cardiovascular 
physiology, coagulation and fibrinolysis, are 
promising candidates for the development of 
new bleeding risk scores in AF.
We tested characteristics of plasma fibrin 
clot structure as potential new biomarkers 
which might help predict bleeding in patients 
with AF, given evidence indicating that fibrin 
clots composed of thinner fibers, which are 
more compact and less permeable, are less sus‑
ceptible to fibrinolysis.43 Recently, dense fibrin 
fiber networks, characterized by low plasma 
clot permeability, have been described as an in‑
dependent predictor of both thromboembol‑
ic events and major bleedings in patients with 
AF on VKA.4 4 We reported that patients with 
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renal function. Of note, renal function may be 
overestimated in underweight patients due to 
their reduced muscle mass (especially when cal‑
culated with the Modification of Diet in Renal 
Disease formula). Compared with warfarin, all 
4 NOACs showed consistent efficacy and safe‑
ty in patients with mild to moderate CKD com‑
pared with non ‑CKD patients in the respective 
subgroup analyses of pivotal NOAC trials.40,61-63 
The ARISTOTLE trial data analysis suggests 
that the bleeding benefit with apixaban com‑
pared with warfarin becomes more prominent 
at lower creatinine clearance (CrCl) values, while 
the stroke reduction benefit is maintained.40,60 
In contrast, the bleeding benefit of dabigatran 
at a dose of 110 mg twice a day over warfarin 
was not observed in patients with CrCl of less 
than 50 ml/min while a similar stroke risk re‑
duction compared with VKA was maintained.62
All available trials on NOACs essential‑
ly excluded patients with a CrCl of less than 
30 ml/min (except for a few patients on apix‑
aban with CrCl 25–30 ml/min in the ARISTO‑
TLE trial). Rivaroxaban, apixaban, and edoxa‑
ban (but not dabigatran) are approved in Europe 
for the use in patients with severe CKD (Stage 
4, ie, a CrCl of 15–29 ml/min), with the reduced 
dose regimen. In Europe, NOACs should not be 
prescribed to patients with AF and severe renal 
dysfunction (CrCl <15 ml/min) as well as to pa‑
tients on dialysis, whereas in the United States, 
apixaban was approved for hemodialyzed pa‑
tients in 2014. Since VKA use leads to a high risk 
of bleeding in this subset of patients, the deci‑
sion to use a VKA in such patients is challenging 
and should be based on the individual patient’s 
as such increases the risk of bleeding.56 Body 
weight of 60 kg or less is a dose ‑reduction crite‑
rion for apixaban.57 In the largest study evaluat‑
ing NOACs in relation to body weight in patients 
with AF, apixaban was at least as efficacious as 
warfarin but safer across the range of weight, 
with the greatest reduction in the risk of bleed‑
ing and hemorrhagic stroke in the group with 
body weight of 60 kg or less.55 In patients with 
very low body weight (<50 kg), dabigatran’s ef‑
ficacy and safety were similar to those observed 
in the remainder of the study cohort.58 However, 
observational studies suggested that low body 
mass index (<23.9 kg/m2) may predict bleeding 
in patients on dabigatran.59 Of note, frequently 
coexisting renal insufficiency may make dabiga‑
tran a less preferable option for the underweight 
older patients with AF. Patients with low body 
weight on oral anticoagulation should be mon‑
itored for bleeding risk.
Chronic kidney disease Patients with AF and 
chronic kidney disease (CKD) have an increased 
morbidity and mortality due to their excessive 
risk for both thromboembolic and severe bleed‑
ing events, and risk stratification and treatment 
of patients with AF and CKD may be challeng‑
ing.60 All NOACs are eliminated by the kidneys, 
albeit to a different extent with the maximum 
value for dabigatran (80%), whereas 50%, 35%, 
and 27% of edoxaban, rivaroxaban, and apixa‑
ban, respectively, are cleared via the kidneys in 
unchanged form. In all patients on NOACs, renal 
function needs to be monitored at least yearly. 
Importantly, intercurrent acute illness (eg, infec‑
tions, acute heart failure) may transiently affect 
FIGURE 2   Major bleeding rates among atrial fibrillation patients aged ≥75 years treated with non–vitamin K antagonist oral anticoagulants and warfarin based 
on landmark randomized controlled trials 
Abbreviations: bid, twice daily; HR, hazard ratio; others, see FIGURE 1
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bleeding. The advantage of NOACs over warfarin 
in the bleeding risk reduction was observed in 
the groups with nonalcoholic and nonadvanced 
cirrhosis. In patients with advanced cirrhosis 
who presented with any complications such as 
ascites, encephalopathy, spontaneous bacteri‑
al peritonitis, or prior bleeding from esopha‑
geal varices, this benefit from NOACs was di‑
minished, presumably due to reduced drug me‑
tabolism and impaired hepatobiliary excretion.59
Of note, hepatotoxicity has been observed 
in less than 1% of patients with AF in the NOAC 
trials at a similar rate to the warfarin arms.67 
Usually, drug withdrawal normalized liver func‑
tion markers within a few days. Search for un‑
derlying liver pathologies and hepatotoxic drugs, 
for example, amiodarone, should be performed.
Prior serious bleeding In most bleedings due to 
secondary (eg, bleeding post ‑trauma) or revers‑
ible causes (eg, GI bleed due to colon polyps or 
peptic ulcer), anticoagulation can be resumed 
once the cause of the bleed is eliminated. Re‑
‑initiation of anticoagulation should be consid‑
ered after 4 to 7 days after a GI bleed if benefits 
outweigh potential risks of re ‑bleeding.68,69 Fac‑
tors that need to be taken into consideration 
before preinitiation or withholding of antico‑
agulation include identification of the bleed‑
ing site, presence of reversible / treatable cause 
of bleeding and angiodysplasia in the GI tract, 
older age, chronic alcohol abuse, and need for 
antiplatelet therapy. Results from observation‑
al studies on patients after GI bleeding sug‑
gest benefits from resuming anticoagulation 
without an increase in recurrent GI bleeding 
in the majority of patients with AF.70
risk of stroke, anticipated net benefit, and pa‑
tient’s preferences.60
Regarding patients with AF after kidney 
transplantation, high ‑quality evidence is lack‑
ing, but NOACs might be used with the dosing 
regimen adjusted to the estimated renal func‑
tion, and consideration of possible drug–drug 
interactions between NOACs and immunosup‑
pressive agents.6 4
Liver disease Patients with active liver dis‑
ease, including cirrhosis, or those with persis‑
tent (2 measurments at least 7 days apart) ele‑
vation of the liver enzymes or bilirubin (eg, al‑
anine transaminase or aspartate transami‑
nase ≥2–3 times the upper limit of normal or 
total bilirubin ≥1.5 times the upper limit of nor‑
mal) were excluded from the landmark NOAC 
trials in AF.13,14,18,58 NOACs are contraindicat‑
ed in patients with hepatic disease associated 
with coagulopathy and clinically relevant bleed‑
ing risk including class C cirrhosis according to 
the Child–Pugh classification, while rivaroxa‑
ban should not be used even in patients with AF 
and Child–Pugh class B cirrhosis due to a more 
than a 2‑fold increase in drug exposure in these 
individuals.65 Dabigatran, apixaban, and edox‑
aban may be used with caution in patients with 
Child–Pugh class B cirrhosis. A reduced ‑dose 
NOAC should be considered in patients with liv‑
er disease at high bleeding risk, and close sur‑
veillance is advised in this subset. Lee et al,66 in 
a registry ‑based study in patients with liver cir‑
rhosis treated predominantly with low ‑dose dab‑
igatran and rivaroxaban, demonstrated the risk 
of stroke / SE and ICB comparable with warfarin 
and a reduced risk of major bleeding including GI 
FIGURE 3   Major gastrointestinal (GI) bleeding rates in patients with atrial fibrillation treated with non –vitamin K antagonist oral anticoagulants versus those on 
warfarin (based on Chai ‑Adisaksopha)12 
Abbreviations: GI, gastrointestinal; others, see FIGURES 1 and 2
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recommendations, unless the cause of the bleed‑
ing (like uncontrolled hypertension, aneurysm 
or arteriovenous malformation, or triple anti‑
thrombotic therapy) has been reversed.7,7 2 Rea‑
sons for not resuming or initiating anticoagu‑
lation in patients with ICB and AF should be 
assessed on an individual basis.7 3 Patients with 
(probable) cerebral amyloid angiopathy have 
a very high risk of recurrent ICB and should 
not be anticoagulated.74 Adequate blood pres‑
sure control is of paramount importance in all 
patients after ICB.7 3 Left atrial appendage occlu‑
sion may be considered in some patients with 
AF after ICB as well as after recurrent intracta‑
ble or untreatable major bleeding, although evi‑
dence on the role of left atrial appendage occlu‑
sion in such patients  lacking.7,75 However, anti‑
platelet treatment for at least 1 month post left 
atrial appendage occlusion is associated with 
increased bleeding risk in such patients, which 
should be taken into account especially in elder‑
ly patients with AF.
Thrombocytopenia It is estimated that up to 
3% of patients with AF have thrombocytopenia, 
defined as a platelet count below 100 000/µl.76 
Although thrombocytopenia does not pro‑
tect against thromboembolic events, patients 
with AF with platelet count below 90 000 to 
100 000/µl were excluded from the landmark 
phase 3 NOAC trials.51-53
The current guidelines for the management 
of patients with AF do not provide any recom‑
mendations for the use of NOACs in thrombo‑
cytopenic patients.68,69
In a retrospective study, the use of VKAs 
in patients with moderate thrombocytopenia 
of 50 000 to 100 000/µl (mean platelet count, 
87 900/µl) who had AF or VTE was associated 
with a 3 ‑fold higher incidence of minor bleed‑
ing (5.55 vs 1.84 per 100 patient ‑years) and 
In patients with AF at a high ‑risk of GI bleed‑
ing, the 2016 European Society of Cardiolo‑
gy guidelines recommend using VKAs or NO‑
ACs other than dabigatran at a dose of 150 mg 
bid, rivaroxaban, 20 mg once daily, and edox‑
aban, 60 mg once daily (class IIa, level of evi‑
dence B). The elimination of modifiable bleed‑
ing risk factors, in particular alcohol abuse and 
cyklooxygenase ‑1 inhibitors, is of key impor‑
tance to minimize bleeding risk on anticoagu‑
lation. Importantly, the landmark AF RCTs indi‑
cate that, compared with warfarin, the risk of GI 
bleeds is not increased for dabigatran 110 mg bid 
and apixaban 5 mg bid7 (FIGURE 3).
Co ‑therapy with protein pump inhibitors 
is associated with 25% to 51% less hospitaliza‑
tions due to GI bleeding during VKAs and NO‑
ACs use, with the most pronounced reduction ob‑
served for dabigatran, as the result of reduced di‑
rect mucosal toxicity of the drug and decreased 
dabigatran bioavailability7 1 (FIGURE 4). Approxi‑
mately 1 in 12 major bleedings in patients receiv‑
ing warfarin or dabigatran is caused by an un‑
derlying cancer of the GI tract, most common‑
ly colorectal cancer. Cancer ‑related bleedings 
manifest sooner and are more frequently chron‑
ic than those of a nonmalignant or unidenti‑
fied source. There was no difference observed 
in the short ‑term outcome between dabiga‑
tran‑ and warfarin ‑related bleedings; however, 
the majority of patients required blood transfu‑
sions and prolonged hospital stay.71 Further pro‑
spective studies are required to determine if GI 
cancer screening before and after initiation of 
anticoagulation, in particular the most common 
colorectal cancer, may allow earlier cancer detec‑
tion and treatment; however, baseline screening 
in high ‑risk populations should be considered.
A  history of a  spontaneous ICB is a  con‑
traindication for anticoagulation with VKAs 
and NOACs based on the manufacturer’s 
FIGURE 4   
The incidence of 
hospitalizations for upper 
gastrointestinal (GI) 
bleeding in relation to oral 
anticoagulants and proton‑
‑pump inhibitor (PPI) 
cotherapy 
(based on Ray et al71) 
Abbreviations: IRR, incidence 
rate ratio; RD, risk difference 
per 10 000 person ‑years; 
others, see FIGURE 1
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The 2019 ISTH guidelines regarding the use 
of NOACs in patients with AF and cancer re‑
ceiving chemotherapy recommend individu‑
alized anticoagulation, based on the risk of 
stroke, bleeding, and patient preferences. NO‑
ACs should be considered in patients with clin‑
ically relevant interactions between VKAs and 
anticancer medications that are not expected 
with NOACs, or in those unable to comply with 
INR monitoring. The use of NOACs over VKAs 
or heparins is suggested in patients on chemo‑
therapy with newly diagnosed AF, with the ex‑
ception of patients with luminal GI cancer and 
an intact primary tumor or active GI mucosal 
abnormalities.86 In a recent study in patients 
with colorectal cancer after surgery and first‑
‑line chemotherapy treated with a NOAC, main‑
ly rivaroxaban in a dose of 20 mg daily, the rate 
of TIA and stroke as well as major bleeding 
was relatively low, 4.0% and 1.9%, respective‑
ly. A reduced dose of a NOAC was associated 
with higher risk of thromboembolic events.87 
Real ‑world data on the effectiveness and safe‑
ty of NOACs in oncological patients suggest 
a clear benefit, especially in patients with fa‑
vorable prognosis; however, the safety in spe‑
cific subgroups of patients with cancer remains 
to be clarified.88,89
Reversal agents The use of specific and non‑
specific reversal agents in patients with AF on 
NOACs should be restricted to life ‑threatening 
situations, predominantly ICB or posttraumat‑
ic bleeding.90
Idarucizumab is a humanized monoclonal an‑
tibody fragment which is a specific reversal agent 
for dabigatran. It binds with 350 times higher 
affinity than thrombin to free and thrombin‑
‑bound dabigatran within minutes. This reac‑
tion is irreversible.90
Idarucizumab was approved in Europe in 
November 2015. It has become the standard 
of care for the reversal of dabigatran when it 
is available. The RE ‑VERSE AD (Reversal Ef‑
fects of Idarucizumab on Active Dabigatran) 
study assessed the safety and efficacy of 5 g 
idarucizumab (administered as 2 rapid 2.5 g 
intravenous boluses) in dabigatran ‑treated pa‑
tients who presented with uncontrolled or life‑
‑threatening bleeding (group A) or nonbleed‑
ing patients who required emergent surgery or 
intervention (group B). The primary outcome 
of the RE‑VERSE AD study was maximum per‑
centage reversal of the anticoagulant effect of 
dabigatran. The RE ‑VERSE AD study, published 
as an interim analysis of the first 90 patients 
in 20159 1 and then a final analysis of 503 pa‑
tients in 2017,92 showed the utility of idaruci‑
zumab in the 2 groups of patients. Now, idaru‑
cizumab is the best therapeutic option for pa‑
tients with AF on dabigatran who experience 
life ‑threatening bleeding.
a tendency toward a higher risk of major bleed‑
ing. All the recorded bleeding complications oc‑
curred at INRs above 2.5, which suggests us‑
ing narrower INR targets and lower intensity 
oral anticoagulation.7 7 Sadowska et al76 dem‑
onstrated the acceptable safety and effective‑
ness of anticoagulation with NOAC at reduced 
doses in a cohort of patients with AF with mod‑
erate thrombocytopenia (mean platelet count, 
78 000/µl). The risk of bleeding was unaffect‑
ed by the type of NOAC (rivaroxaban, 15 mg 
once daily; dabigatran, 110 mg bid; or apixa‑
ban, 2.5 mg bid), and was predicted only by age. 
Despite the dose reduction of a NOAC, simi‑
lar rates of stroke or TIA and death were ob‑
served in thrombocytopenic and normocyto‑
penic patients. Of note, several cases of NOAC‑
‑induced thrombocytopenia have been reported 
in the literature, which supports platelet count 
monitoring during treatment.78
In patients with severe thrombocytopenia 
(<50 000/µl) and AF, the anticoagulation should 
be individualized and closely monitored given 
the lack of evidence from trials.
Cancer patients Atrial fibrillation is present in 
approximately 5% of patients with cancer at the 
time of diagnosis or within the first months of 
treatment.79 Based on the current guidelines, 
about 80% of patients with AF and cancer had 
indications for chronic anticoagulation.80 Of 
note, cancer is associated with an increased risk 
of bleeding related to thrombocytopenia, metas‑
tases, kidney and liver damage, vessel damage 
caused by a tumor infiltrating its wall, invasive 
procedures, and radiation therapy.69
Regarding patients with cancer and AF, most 
data are from observational studies.81 Random‑
ized studies of patients with cancer and VTE, 
including the Hokusai VTE Cancer trial with 
edoxaban and SELECT ‑D (Anticoagulation Ther‑
apy in Selected Cancer Patients at Risk of Re‑
currence of Venous Thromboembolism) trial 
with rivaroxaban, showed that NOACs use com‑
pared with dalteparin was associated with re‑
duction in the recurrence rate of VTE and in‑
creased risk of major bleeding, mainly GI bleed‑
ing. The highest bleeding risk was observed in 
patients with esophageal, gastroesophageal, and 
urologic cancer.82,83
Shah et al,84 in a registry ‑based study in a pop‑
ulation of patients with AF and cancer, reported 
lower or similar rates of bleeding and stroke, and 
a lower rate of VTE in NOAC users as compared 
with VKA users. Although limited by the sample 
size, the lowest rates of VTE and severe bleed‑
ing were observed for apixaban. Data from reg‑
istries suggested a higher number of hemor‑
rhagic complications in patients with cancer 
and AF with concomitant metastatic disease, 
advanced CKD, recent bleeding (<30 days), and 
longer immobility.85
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had fatal ischemic stroke at 5 and 15 days af‑
ter the index bleeding.96
Analysis of 460 bleeds observed in patients 
on NOACs showed that almost 20% of those 
patients received vitamin K, which is useless in 
such clinical situations.94 It has absolutely no 
possibility of any effect, but was given proba‑
bly because many of these patients had a pro‑
longed INR due to rivaroxaban.97
Tranexamic acid, an antifibrinolytic agent ef‑
fective in trauma or postpartum hemorrhages, 
acts as a lysine analog that impairs plasminogen 
activation on fibrin. In patients on NOACs, its 
efficacy is uncertain; however, it might be used.
Fresh frozen plasma is ineffective in patients 
bleeding on NOACs but was used in about 10% 
of patients reported by Xu Y et al.94 Fresh frozen 
plasma may be used as a plasma volume expand‑
er in patients following transfusions; however, 
its shortcomings are numerous, including risk 
of transfusion reactions, and acute heart failure.
Experts strongly recommend that an institu‑
tional policy concerning bleeding management is 
defined in every hospital. In patients on NOACs, 
the recommendations, including a protocol con‑
taining the availability and indications of spe‑
cific and nonspecific reversal agents, should be 
developed by cardiologists, hemostasis experts, 
intensivists and others, and this policy should 
be easily accessible for all physicians in a given 
institution.31,68
Patient preferences and knowledge in reduc-
ing bleeding risk Optimal treatment strategies 
for stroke prevention incorporate patient prefer‑
ences and values, which may differ from those of 
the physician. Results from a survey suggest that 
patients with AF who initiate oral anticoagulation 
are willing to sustain 4 major bleeds to avoid 1 se‑
rious stroke.98 About half of the patients, main‑
ly older, with minor or major bleeds on anticoag‑
ulation and without history of cerebrovascular 
events, accept a low number of bleeds (0–3). Our 
recent findings confirmed that patients with AF 
fear a major stroke more than bleeding, but they 
are less willing to accept such adverse events after 
a serious bleed in the past as well as in the pres‑
ence of persistent minor bleeding, for example, 
easy bruising.98 From a practical point of view, 
it is important to remember that only 1 out of 2 
patients with AF treated with NOACs or VKAs 
is aware that the safest painkiller is paracetamol, 
and 1 out of 4 patients knows what to do when 
an anticoagulant dose is missed. Among patients 
with AF, women, patients with diabetes, prosthet‑
ic heart valve, and minor bleedings were found 
to be better informed about those issues.99 Better 
education about the disease and anticoagulation 
is likely to improve compliance and therapy out‑
comes in patients with AF,100 and activities aim‑
ing at improving knowledge should be strongly 
supported in everyday practice.
Andexanet alfa, which binds with high affin‑
ity to direct factor Xa inhibitors and also low‑
‑molecular ‑weight heparins and fondaparinux,93 
is a modified human recombinant factor Xa de‑
coy protein that lacks catalytical activity follow‑
ing replacement of an active ‑site serine with ala‑
nine and with removal of the membrane ‑binding 
domain, which precludes this protein to partic‑
ipate in the formation of the prothrombinase 
complex.15,92 Because of its pharmacodynamic 
half ‑life of 1 hour, andexanet was administered 
as a bolus followed by an infusion, which leads 
to the normalization of anti–factor Xa activity 
within 2 hours.
The results of 2 RCTs (Andexanet Alfa, a Nov‑
el Antidote to the Anticoagulation Effects of 
FXA Inhibitors trials [ANNEXA]) performed 
in healthy volunteers aged 50 to 75 years who 
received apixaban (ANNEXA ‑A) and rivaroxa‑
ban (ANNEXA ‑R)93 demonstrated the efficacy 
and safety of andexanet alfa. The phase 3b to 
4 ANNEXA ‑4 study confirmed the efficacy and 
safety of andexanet alfa in patients treated with 
factor Xa inhibitors with acute major bleeding.
In May 2018, andexanet alfa, which is a spe‑
cific reversal agent for oral factor Xa inhibitors, 
was approved in the United States, and in 2019 
in Europe, but currently it is unavailable in many 
countries. For this reason, the available Xa in‑
hibitor reversal strategies rely on nonspecific 
strategies of unknown effectiveness, in partic‑
ular prothrombin complex concentrates (PCCs). 
Prothrombin complex concentrates are plasma‑
‑derived products that contain 3 (factors II, IX, 
and X) or 4 (addition of factor VII) clotting fac‑
tors in addition to variable amounts of hepa‑
rin and natural coagulation inhibitors, protein 
C and protein S, which are used among others 
to reverse anticoagulant effects of VKAs in pa‑
tients with severe bleeding. Activated PCC (also 
known as factor VIII inhibitor bypassing activ‑
ity) contains mostly activated factor VII along 
with mainly nonactivated factors II, IX, and X. 
A dose of 50 U/kg of PCC or activated PCC is rec‑
ommend in patients treated with rivaroxaban or 
apixaban if life ‑threatening bleeding occurs.16,19
A  prospective multicenter observational 
study showed that in the real world,94 reversal 
strategies in bleeding patients on rivaroxaban 
or apixaban differ largely. A Swedish case series 
of 84 bleeding patients (75% with AF) who re‑
quired reversal of factor Xa inhibition after 9 
to 16 hours since the last dose of the anticoag‑
ulant showed that in most cases (70% ICB and 
16% GI bleeds), PCC at a dose of 2000 units was 
used in patients with body weight of 65 kg or 
more, while 1500 units were administered in 
patients weighted below 65 kg.95 No hemostatic 
effect of PCC was observed in 30.9% of patients, 
largely in those with ICB. Of note, 15 patients 
died, including 13 patients following ICB (30‑
‑day mortality rate, 32%), whereas 2 patients 
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include: 1) thrombolytic therapy in stroke, 2) sur‑
gery or invasive procedure, 3) a need for immedi‑
ate reversal of anticoagulation, 4) extreme body 
weight, 5) substantial drug–drug interactions 
(eg, after transplantation, anti ‑HIV treatment), 
6) suspected noncompliance or overdosage in 
case of thrombosis or hemorrhage, respectively.97
Conclusions Overall, NOACs were comparable 
or superior to VKAs in most patients with AF as 
shown in RCTs and observational studies. Indi‑
vidualization of anticoagulant therapy based on 
benefit and safety profiles as well as patient char‑
acteristics should be considered in particular in 
patients with AF at elevated risk of bleeding, such 
as the elderly patients with several comorbidities 
and those with cancer (TABLE 2). Given a high risk of 
stroke in most patients with AF as compared with 
bleeding risk, appropriate dosing regimen should 
be used and reduced ‑dose regimen should be re‑
stricted to the recommended settings. Modifiable 
bleeding risk factors such as use of nonsteroidal 
anti ‑inflammatory drugs available over the coun‑
ter should be eliminated whenever feasible.
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NOAC Standard	dose Dose	reduction
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Based on clinical and pharmacokinetic data, dose adjustment or NOAC change should be considered 
if: age ≥75 years, cancer, concomitant antiplatelet drugs or significant drug–drug interactions, 
frailty / fall risk, chronic kidney disease stage 4, hepatic injury, history of bleeding or predisposition, 
recent surgery on critical organ and thrombocytopenia.
Abbreviations: CrCl, creatinine clearance; NOAC, non –vitamin K antagonist oral anticoagulant; 
SmPC, summary of product characteristics
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